Glucocorticoids in multiple myeloma: past, present, and future

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Glucocorticoids are fundamental in treating multiple myeloma, used in both initial and later-stage disease.
• While effective alone, they are now combined with novel agents to enhance clinical response rates.
• Steroid toxicity can restrict dosage and negatively affect patient quality of life.

Purpose of the Study:

• To trace the historical integration and sustained use of glucocorticoids in multiple myeloma therapy.
• To explore the mechanisms underlying glucocorticoid sensitivity and resistance in multiple myeloma.
• To identify future research avenues for assessing steroid responsiveness.

Main Methods:

• Historical review of glucocorticoid use in multiple myeloma.
• Analysis of mechanisms of glucocorticoid sensitivity and resistance.
• Literature review for potential future research directions.

Main Results:

• Glucocorticoids have a long-standing role in multiple myeloma treatment, both as single agents and in combination therapies.
• Understanding resistance mechanisms is crucial for optimizing treatment efficacy.
• Future research can guide personalized steroid utilization.

Conclusions:

• Glucocorticoids remain a cornerstone of multiple myeloma management.
• Further investigation into steroid responsiveness is needed to optimize their use and identify when they may not be beneficial.
• Optimizing steroid utilization can improve patient outcomes and quality of life.